BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 29107152)

  • 1. The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study.
    Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio HM; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ
    J Hepatol; 2018 Mar; 68(3):393-401. PubMed ID: 29107152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales.
    Shah SHBU; Alavi M; Hajarizadeh B; Matthews GV; Martinello M; Danta M; Amin J; Law MG; George J; Valerio H; Dore GJ
    JHEP Rep; 2022 Oct; 4(10):100552. PubMed ID: 36119722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study.
    Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio H; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ
    J Viral Hepat; 2018 May; 25(5):473-481. PubMed ID: 29194861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hospitalization of hepatitis C-diagnosed individuals in Scotland for decompensated cirrhosis: a population-based record-linkage study.
    McDonald SA; Hutchinson SJ; Bird SM; Mills PR; Robertson C; Dillon JF; Williams T; Goldberg DJ
    Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):49-57. PubMed ID: 19773667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment.
    Aspinall EJ; Hutchinson SJ; Janjua NZ; Grebely J; Yu A; Alavi M; Amin J; Goldberg DJ; Innes H; Law M; Walter SR; Krajden M; Dore GJ
    J Hepatol; 2015 Feb; 62(2):269-77. PubMed ID: 25200903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inpatient hospital burden of hepatitis C-diagnosed patients with decompensated cirrhosis.
    McDonald SA; Innes HA; Aspinall EJ; Hayes PC; Alavi M; Valerio H; Goldberg DJ; Hutchinson SJ
    Liver Int; 2018 Aug; 38(8):1402-1410. PubMed ID: 29288595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness.
    Innes HA; Hutchinson SJ; Barclay S; Cadzow E; Dillon JF; Fraser A; Goldberg DJ; Mills PR; McDonald SA; Morris J; Stanley A; Hayes P;
    Hepatology; 2013 Feb; 57(2):451-60. PubMed ID: 22961861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
    J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of new direct-acting antiviral therapy on the prevalence and undiagnosed proportion of chronic hepatitis C infection.
    Forouzannia F; Hamadeh A; Passos-Castilho AM; Erman A; Yu A; Feng Z; Janjua NZ; Sander B; Greenaway C; Wong WWL
    Liver Int; 2024 Jun; 44(6):1383-1395. PubMed ID: 38445848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
    Belli LS; Perricone G; Adam R; Cortesi PA; Strazzabosco M; Facchetti R; Karam V; Salizzoni M; Andujar RL; Fondevila C; De Simone P; Morelli C; Fabregat-Prous J; Samuel D; Agarwaal K; Moreno Gonzales E; Charco R; Zieniewicz K; De Carlis L; Duvoux C;
    J Hepatol; 2018 Oct; 69(4):810-817. PubMed ID: 29940268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
    Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.
    Janjua NZ; Islam N; Wong J; Yoshida EM; Ramji A; Samji H; Butt ZA; Chong M; Cook D; Alvarez M; Darvishian M; Tyndall M; Krajden M
    J Viral Hepat; 2017 Aug; 24(8):624-630. PubMed ID: 28130810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
    Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
    Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of alcohol use disorders on the burden of chronic hepatitis C in France, 2008-2013: A nationwide retrospective cohort study.
    Schwarzinger M; Baillot S; Yazdanpanah Y; Rehm J; Mallet V
    J Hepatol; 2017 Sep; 67(3):454-461. PubMed ID: 28396173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study.
    Alavi M; Law MG; Grebely J; Amin J; Hajarizadeh B; George J; Dore GJ
    J Hepatol; 2016 Nov; 65(5):879-887. PubMed ID: 27401548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012.
    Alavi M; Grebely J; Hajarizadeh B; Amin J; Larney S; Law MG; George J; Degenhardt L; Dore GJ
    BMC Infect Dis; 2018 May; 18(1):215. PubMed ID: 29743015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
    Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
    J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study.
    Hamill V; Wong S; Benselin J; Krajden M; Hayes PC; Mutimer D; Yu A; Dillon JF; Gelson W; Velásquez García HA; Yeung A; Johnson P; Barclay ST; Alvarez M; Toyoda H; Agarwal K; Fraser A; Bartlett S; Aldersley M; Bathgate A; Binka M; Richardson P; Morling JR; Ryder SD; MacDonald D; Hutchinson S; Barnes E; Guha IN; Irving WL; Janjua NZ; Innes H
    BMJ; 2023 Aug; 382():e074001. PubMed ID: 37532284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era.
    McDonald SA; Innes HA; Aspinall E; Hayes PC; Alavi M; Valerio H; Goldberg DJ; Hutchinson SJ
    J Viral Hepat; 2017 Apr; 24(4):295-303. PubMed ID: 27885753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.